Bone formation markers in patients with glucocorticoid-induced osteoporosis treated with teriparatide or alendronate
| Autor: | Mayme Wong, Kenneth G. Saag, Richard Eastell, Margaret R. Warner, Alan L. Burshell, Peiqi Chen, John H. Krege |
|---|---|
| Rok vydání: | 2009 |
| Předmět: |
Adult
Male medicine.medical_specialty Histology Bone density Physiology Endocrinology Diabetes and Metabolism Osteoporosis Osteocalcin Gastroenterology Subcutaneous injection Double-Blind Method Bone Density Osteogenesis Internal medicine Teriparatide medicine Humans Glucocorticoids Aged Chi-Square Distribution biology Alendronate Bone Density Conservation Agents business.industry Alendronic acid Middle Aged medicine.disease Peptide Fragments Procollagen peptidase Endocrinology Treatment Outcome biology.protein Female business Glucocorticoid Biomarkers Procollagen medicine.drug |
| Zdroj: | Bone. 46(4) |
| ISSN: | 1873-2763 |
| Popis: | Reduced osteoblast function is a primary defect in glucocorticoid-induced osteoporosis (GIO), and is reflected by decreased biochemical markers of bone formation, such as serum osteocalcin (OC) and procollagen type I N-terminal propeptide (PINP). This analysis compared the effects of teriparatide and alendronate on OC and PINP in patients with GIO. In a double-blind study, women (N=159) and men (N=38) with GIO were randomized to either teriparatide 20 mug/day by subcutaneous injection or to alendronate 10 mg/day orally. OC and PINP were measured in fasting-state serum samples obtained at baseline and at 1, 6, 18, and 36 months. Baseline bone formation markers were below the reference interval (low) in 33% of patients for OC and in 4% of patients for PINP. On teriparatide therapy, the median OC and PINP levels increased by 92% and 108%, respectively, and this resulted in only 12% and 1% of patients being low at 6 months. On alendronate therapy, the median OC and PINP levels decreased by 40% and 53%, respectively, and this resulted in 68% and 34% of patients being low at 6 months. We conclude that bone formation as determined by surrogate markers was increased in teriparatide-treated patients with GIO and decreased in alendronate-treated patients with GIO. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect